The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.
|Articles|December 1, 2005
New products for 2005
This year's roundup looks at innovations in wound care, hand sanitizers, otoscopy, and vision screening. It also considers helpful online resources?and takes a peek into a virtual time capsule of technology.
Advertisement
Advertisement
Related to this article
The FDA accepted the dersimelagon NDA with priority review for EPP and XLP; a decision on the oral MC1R agonist is expected by February 2027.
Children with atopic dermatitis have higher ADHD risk, particularly with early, severe disease and sleep disturbance, a review found.
Baseline severity and clinical phenotype may help predict response to systemic therapy in children with alopecia areata.
Can you guess the diagnosis?
Can you guess the diagnosis?
Phase 3 data show lebrikizumab improved skin clearance, itch, and quality of life in children with moderate-to-severe atopic dermatitis.
FDA approved obinutuzumab for relapsing or steroid-dependent childhood-onset INS, based on INShore data showing 95.5% vs 73.2% sustained remission.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA approves baricitinib for adolescents with severe alopecia areata
2
FAQ: How should pediatricians hand off teens with diabetes?
3
GLP-1 receptor agonists tied to nutritional deficiencies in children, study finds
4
FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
5